Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...

Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc Good afternoon. My name ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

The global injectable drug delivery devices market size is calculated at USD 565 billion in 2025 and is expected to reach around USD 1,217 billion by ...

The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...

Promising Liver Cancer Therapies such as Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, ...

LONDON, GREATER LONDON, UNITED KINGDOM, February 19, 2025 /EINPresswire / -- Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The global Human Growth Hormone Treatment and Drugs Market is expected to reach a value of around USD 5.26 billion by 2033, ...